Semaglutide vs Tirzepatide: the honest comparison
Tirzepatide produces larger fat loss and stronger glycemic control in head-to-head trials, but Semaglutide has longer real-world safety data and a gentler titration curve. Semaglutide is usually the right starting compound; Tirzepatide is where users step up when Semaglutide plateaus.
Side-by-side facts
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Half-life | Approximately 7 days (once-weekly dosing) | Approximately 5 days (once-weekly dosing) |
| Typical dose | Titration: 0.25 mg (250 mcg) → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly | Titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly |
| Category | GLP-1 / metabolic | GLP-1/GIP / metabolic |
| FDA status | FDA approved as Ozempic (type 2 diabetes), Wegovy (obesity), Rybelsus (oral T2D). Compounded semaglutide is not FDA approved and is under active FDA scrutiny. | FDA approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Compounded tirzepatide currently faces the same FDA scrutiny as semaglutide. |
| Storage | Lyophilized stable refrigerated. | Lyophilized refrigerated preferred. |
What they have in common
Both are injectable incretin-receptor agonists dosed once weekly that suppress appetite, slow gastric emptying, and improve insulin sensitivity. Both are FDA approved for type 2 diabetes and obesity (Semaglutide as Ozempic/Wegovy/Rybelsus, Tirzepatide as Mounjaro/Zepbound).
When to pick Semaglutide
Pick Semaglutide when you want the deepest clinical safety dataset, smoother GI tolerance during titration, or already have good results with Ozempic/Wegovy. It is the conservative choice for first-time GLP-1 users and for anyone where cost of a weekly injection matters — Semaglutide is widely compounded and generally cheaper on the grey market.
When to pick Tirzepatide
Pick Tirzepatide when the goal is maximum weight loss or when Semaglutide has plateaued below target. The SURPASS and SURMOUNT trials showed Tirzepatide consistently produced 15–22% weight reduction at the top dose vs Semaglutide's ~15%. It tends to produce more nausea during titration but better long-term glycemic control.
Can you stack them?
No — you do not stack two GLP-1 agonists. You switch from one to the other. Running them concurrently does not meaningfully increase fat loss and multiplies GI side effects.
The two compounds
Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It slows gastric emptying…
Tirzepatide
Tirzepatide is a synthetic dual incretin agonist activating both GIP and GLP-1 receptors. Clinical trials show weight loss and glycemic e…
Track either compound on iPhone
Peptide Protocol schedules doses, calculates reconstitution, and logs side effects for both — on iPhone, free to download.
See the app →Frequently asked questions
What is the main difference between Semaglutide and Tirzepatide?
Tirzepatide activates both GLP-1 and GIP receptors (dual agonist); Semaglutide activates only GLP-1. The added GIP action is what drives Tirzepatide's larger weight-loss effect and its slightly different side-effect profile.
Can you stack Semaglutide and Tirzepatide?
No — you do not stack two GLP-1 agonists. You switch from one to the other. Running them concurrently does not meaningfully increase fat loss and multiplies GI side effects.
Which is better, Semaglutide or Tirzepatide?
Tirzepatide produces larger fat loss and stronger glycemic control in head-to-head trials, but Semaglutide has longer real-world safety data and a gentler titration curve. Semaglutide is usually the right starting compound; Tirzepatide is where users step up when Semaglutide plateaus.
When should I pick Semaglutide?
Pick Semaglutide when you want the deepest clinical safety dataset, smoother GI tolerance during titration, or already have good results with Ozempic/Wegovy. It is the conservative choice for first-time GLP-1 users and for anyone where cost of a weekly injection matters — Semaglutide is widely compounded and generally cheaper on the grey market.
When should I pick Tirzepatide?
Pick Tirzepatide when the goal is maximum weight loss or when Semaglutide has plateaued below target. The SURPASS and SURMOUNT trials showed Tirzepatide consistently produced 15–22% weight reduction at the top dose vs Semaglutide's ~15%. It tends to produce more nausea during titration but better long-term glycemic control.
Are Semaglutide and Tirzepatide FDA approved?
Semaglutide: FDA approved as Ozempic (type 2 diabetes), Wegovy (obesity), Rybelsus (oral T2D). Compounded semaglutide is not FDA approved and is under active FDA scrutiny. — Tirzepatide: FDA approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Compounded tirzepatide currently faces the same FDA scrutiny as semaglutide.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.